Very recently, the FDA also approved the combination of nivolumab and ipilimumab (the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor) as the first-line treatment for certain patients with metastatic or recurrent NSCLC, with no EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations [17]. Here, CTLA4 is linked to neoplasm.